NCT04886674 is a clinical trial of bovine colostrum in NEC, sponsored by Assiut University.

Who is sponsoring NCT04886674?

NCT04886674 is sponsored by Assiut University.

What drugs are being tested in NCT04886674?

Interventions in NCT04886674: bovine colostrum.

Is NCT04886674 still recruiting?

NCT04886674 is currently status unknown. Last updated 14 May 2021.

Last reviewed 2021-05-14 · How we verify

NCT04886674

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bovine Colostrum in Prevention of Necrotizing Enterocolitis and Sepsis in Very Low Birth Weight Neonates

Status unknown Last updated 14 May 2021

What this trial tests

trial testing bovine colostrum in NEC in 65 participants. Status unknown.

Timeline

1 July 2021

Primary endpoint
30 June 2022

1 July 2022

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	65
Start date	1 July 2021
Primary completion	30 June 2022
Estimated completion	1 July 2022

Drugs / interventions tested

bovine colostrum

Conditions studied

NEC — all drugs for NEC →

Sponsor

Assiut University

Who can join

Adults 1 Day to 5 Months, any sex, with NEC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary Aim: The aim of this study is to investigate the efficacy of bovine colostrum in prevention of necrotizing enterocolitis (NEC) and sepsis in very low birth weight (VLBW) infants. Secondary Aim: To improve outcomes of neonatal sepsis and NEC in the pe-terrms and to decrease their hospital stay.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for NEC

Currently open trials in the same condition.

NCT07191678 — Mechanisms Affecting the Gut of Preterm Infants Receiving Blood Transfusion With Different Enteral Feed Interventions · recruiting
NCT06681129 — Study of Normal Intestinal Development and Disease in Premature and Term Neonates · recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04886674 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 14 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04886674.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing